Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation for continued care.
Presentations on tau to explore its biological role, the development of targeted therapies and biomarkers, and the future integration of these innovations into clinical practice.

The trial will be led by Principal Investigator, Dr. Fathi Abuzgaya, who will collaborate with Sports Medicine Specialists, Drs. Joel Lobo, Kajeandra Ravichandiran and Marcin Kowalczuk as Sub-Investigators, at the Durham Bone & Joint Specialists (DBJS), located in Ontario, Canada.

Three-in-one system integrates large fragment analytics, DNA size selection and fluorometric quantification for long-read sequencing.

The global CDMO services market has expanded rapidly, projected to reach roughly $258 billion by 2028​, reflecting this outsized demand.

The FDA approved this treatment under a compassionate.